Abstract
Aim:
To study the in vitro release of recombinant human tumor necrosis factor-alpha (rHuTNF-α) encapsulated in poly (methoxypolyethyleneglycol cyanoacrylate-co-n-hexadecyl cyanoacrylate) (PEG-PHDCA) nanoparticles, and investigate the influence of methoxypolyethyleneglycol (MePEG) molecular weight and particle size.
Methods:
Three sizes (approximately 80, 170, and 240 nm) of PEGPHDCA nanoparticles loading rHuTNF-α were prepared at different MePEG molecular weights (Mr=2000, 5000, and 10 000) using the double emulsion method. The in vitro rHuTNF-α release was studied in PBS and rat plasma.
Results:
A higher burst-release and cumulative-release rate were observed for nanoparticles with higher MePEG molecular weight or smaller particle size. A decreased cumulative release of rHuTNF-α following the initial burst effect was found in PBS, while the particle sizes remained constant and MePEG liberated. In contrast, in rat plasma, slowly increased cumulative-release profiles were obtained after the burst effect. During a 5-h incubation in rat plasma, more than 50% of the PEGPHDCA nanoparticles degraded.
Conclusion:
The MePEG molecular weight and particle size had an obvious influence on rHuTNF-α release. rHuTNF-α released from PEG-PHDCA nanoparticles in a diffusion-based pattern in PBS, but in a diffusion and erosion-controlled manner in rat plasma.
Similar content being viewed by others
Article PDF
References
Dunn SE, Coombes AGA, Garnett MC, Davis SS, Davies MC, Illum L . In vitro cell interaction and in vivo biodistribution of poly (lactide-co-glycolide) nanospheres surface modified by poloxamer and poloxamine copolymers. J Control Release 1997; 44: 65–76.
Mosqueira VCF, Legrand P, Morgat JL, Vert M, Mysiakine E, Gref R, et al. Biodistribution of long-circulating PEG-grafted nanocapsules in mice: effects of PEG chain length and density. Pharm Res 2001; 18: 1411–19.
Moghimi SM, Hunter AC, Murray JC . Long-circulating and targetspecific nanoparticles: theory to practice. Pharmacol Rev 2001; 53: 283–318.
Brigger I, Dubernet C, Couvreur P . Nanoparticles in cancer therapy and diagnosis. Adv Drug Del Rev 2002; 54: 631–51.
Li YP, Pei YY, Zhou ZH, Zhang XY, Gu ZH, Ding J, et al. Stealth polycyanoacrylate nanoparticles as tumor necrosis factor-alpha carriers: pharmacokinetics and anti-tumor effects. Biol Pharm Bull 2001; 24: 662–5.
Li YP, Zhou ZH, Pei YY, Zhang XY, Gu ZH, Yuan WF . PEGylated polycyanoacrylate nanoparticles as salvicine carriers: synthesis, preparation, and in vitro characterization. Acta Pharmacol Sin 2001; 22: 645–50.
Li YP, Pei YY, Zhou ZH, Zhang XY, Gu ZH, Ding J, et al. PEGylated polycyanoacrylate nanoparticles as tumor necrosis factor-alpha carriers. J Control Release 2001; 71: 287–96.
Zambaux MF, Bonneaux F, Gref R, Dellacherie E, Vigneron C . Protein C-loaded monomethoxypoly (ethylene oxide)-poly (lactic acid) nanoparticles. Int J Pharm 2001; 212: 1–9.
Redhead HM, Davis SS, Illum L . Drug delivery in poly (lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterisation and in vivo evaluation. J Control Release 2001; 70: 353–63.
Peracchia MT, Vauthier C, Desmaele D, Gulik A, Dedieu JC, Demoy M, et al. Pegylated nanoparticles from a novel methoxypolyethylene glycol cyanoacrylate-hexadecyl cyanoacrylate amphiphilic copolymer. Pharm Res 1998; 15: 550–6.
Tobio M, Gref R, Sanchez A, Langer R, Alonso MJ . Stealth PLA-PEG nanoparticles as protein carriers for nasal administration. Pharm Res 1998; 15: 270–5.
Li YP, Pei YY, Zhang XY, Gu ZH, Zhou ZH, Yuang WF, et al. PEGylated PLGA nanoparticles as protein carriers: synthesis preparation and biodistribution in rats. J Control Release 2001; 71: 203–11.
Brigger I, Chaminade P, Desmaele D, Peracchia MT, d'Angelo J, Gurny R, et al. Near infrared with principal component analysis as a novel analytical approach for nanoparticle technology. Pharm Res 2000; 17: 1124–32.
Quellec P, Gref R, Perrin L, Dellacherie E, Sommer F, Verbavatz JM, et al. Protein encapsulation within polyethylene glycol-coated nanospheres. I. Physicochemical characterization. J Biomed Mater Res 1998; 42: 45–54.
Quellec P, Gref R, Dellacherie E, Sommer F, Tran MD, Alonso MJ . Protein encapsulation within poly (ethylene glycol)-coated nanospheres. II. Controlled release properties. J Biomed Mater Res 1999; 47: 388–95.
Passirani C, Barratt G, Devissaguet JP, Labarre D . Interactions of nanoparticles bearing heparin or dextran covalently bound to poly (methyl methacrylate) with the complement system. Life Sci 1998; 62: 775–85.
Lin WJ, Juang LW, Lin CC . Stability and release performance of a series of pegylated copolymeric micelles. Pharm Res 2003; 20: 668–73.
Muller RH, Lherm C, Herbort J, Couvreur P . In vitro model for the degradation of alkylcyanoacrylate nanoparticles. Biomaterials 1990; 11: 590–5.
Avgoustakis K, Beletsi A, Panagi Z, Klepetsanis P, Karydas AG, Ithakissios DS . PLGA-PEG nanoparticles of cisplatin: in vitro nanoparticles degradation, in vitro drug release and in vivo drug residence in blood properties. J Control Release 2002; 79: 123–35.
Gaur U, Sahoo SK, De TK, Ghosh PC, Maitra A, Ghosh PK . Biodistribution of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial system. Int J Pharm 2000; 202: 1–10.
Author information
Authors and Affiliations
Corresponding author
Additional information
Project supported by the Science and Technology Development Foundation of Shanghai (No 0243nm067).
Rights and permissions
About this article
Cite this article
Fang, C., Shi, B. & Pei, Yy. Effect of MePEG molecular weight and particle size on in vitro release of tumor necrosis factor-α-loaded nanoparticles. Acta Pharmacol Sin 26, 242–249 (2005). https://doi.org/10.1111/j.1745-7254.2005.00537.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2005.00537.x
Keywords
This article is cited by
-
Pharmaceutical perspectives for the delivery of TNF-α in cancer therapy
Journal of Pharmaceutical Investigation (2012)